These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 38044341)

  • 1. PD-1-positive cells contribute to the diagnosis of inflammatory bowel disease and can aid in predicting response to vedolizumab.
    Kim MK; Jo SI; Kim SY; Lim H; Kang HS; Moon SH; Ye BD; Soh JS; Hwang SW
    Sci Rep; 2023 Dec; 13(1):21329. PubMed ID: 38044341
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of Vedolizumab in a Nationwide Cohort of Elderly Inflammatory Bowel Disease Patients.
    Khan N; Pernes T; Weiss A; Trivedi C; Patel M; Medvedeva E; Xie D; Yang YX
    Inflamm Bowel Dis; 2022 May; 28(5):734-744. PubMed ID: 34245261
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Transcriptional Behavior of Regulatory T Cells Predicts IBD Patient Responses to Vedolizumab Therapy.
    Abreu MT; Davies JM; Quintero MA; Delmas A; Diaz S; Martinez CD; Venables T; Reich A; Crynen G; Deshpande AR; Kerman DH; Damas OM; Fernandez I; Santander AM; Pignac-Kobinger J; Burgueno JF; Sundrud MS
    Inflamm Bowel Dis; 2022 Dec; 28(12):1800-1812. PubMed ID: 35993552
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Outcome of elective switching to vedolizumab in inflammatory bowel disease patients under tumor necrosis factor antagonist-maintained clinical remission.
    Wang Y; Wang J; Pekow J; Dalal S; Cohen RD; Ollech J; Israel A; Shogan BD; Micic D; Cannon L; Umanskiy K; Hurst R; Hyman N; Rubin DT; Sakuraba A
    J Gastroenterol Hepatol; 2019 Dec; 34(12):2090-2095. PubMed ID: 31169926
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vedolizumab Is Safe and Efficacious for the Treatment of Pediatric-Onset Inflammatory Bowel Disease Patients Who Fail a Primary Biologic Agent.
    Choi S; Kim ES; Kwon Y; Kim MJ; Choe YH; Choe BH; Kang B
    J Korean Med Sci; 2022 Sep; 37(37):e282. PubMed ID: 36163478
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Real-life efficacy of vedolizumab on endoscopic healing in inflammatory bowel disease - A nationwide Hungarian cohort study.
    Bor R; Fábián A; Matuz M; Szepes Z; Farkas K; Miheller P; Szamosi T; Vincze Á; Rutka M; Szántó K; Bálint A; Nagy F; Milassin Á; Tóth T; Zsigmond F; Bajor J; Müllner K; Lakner L; Papp M; Salamon Á; Horváth G; Sarang K; Schäfer E; Sarlós P; Palatka K; Molnár T
    Expert Opin Biol Ther; 2020 Feb; 20(2):205-213. PubMed ID: 31782939
    [No Abstract]   [Full Text] [Related]  

  • 7. Colonic Epithelial Permeability to Ions Is Restored after Vedolizumab Treatment and May Predict Clinical Response in Inflammatory Bowel Disease Patients.
    Cicala M; Gori M; Balestrieri P; Altomare A; Tullio A; Di Cola S; Dejongh S; Graziani MG; Pagnini C; Carotti S; Perrone G; Ribolsi M; Fiorani M; Guarino MPL; Farré R
    Int J Mol Sci; 2024 May; 25(11):. PubMed ID: 38892004
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Factors influencing the outcome of vedolizumab treatment: Real-life data with objective outcome measurements.
    Mader O; Juillerat P; Biedermann L; Michetti P; Hruz P; Pittet V; Rogler G; Zahnd-Straumann N; Seibold F
    United European Gastroenterol J; 2021 Apr; 9(3):398-406. PubMed ID: 33203339
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Real-world biologic treatment and associated cost in patients with inflammatory bowel disease.
    Brandes A; Groth A; Gottschalk F; Wilke T; Ratsch BA; Orzechowski HD; Fuchs A; Deiters B; Bokemeyer B
    Z Gastroenterol; 2019 Jul; 57(7):843-851. PubMed ID: 31288280
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic drug monitoring in inflammatory bowel disease patients on vedolizumab.
    Ansari M; Glassner K; Irani M; Saleh A; Wang L; Ezeana C; Wong S; Perry C; Abraham B
    J Dig Dis; 2024 Feb; 25(2):91-99. PubMed ID: 38599667
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low Rate of Drug Discontinuation, Frequent Need for Dose Adjustment, and No Association with Development of New Arthralgia in Patients Treated with Vedolizumab: Results from a Tertiary Referral IBD Center.
    Reinglas J; Gonczi L; Verdon C; Bessissow T; Afif W; Wild G; Seidman E; Bitton A; Lakatos PL
    Dig Dis Sci; 2020 Jul; 65(7):2046-2053. PubMed ID: 31813132
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Articular manifestations in patients with inflammatory bowel disease treated with vedolizumab.
    Dupré A; Collins M; Nocturne G; Carbonnel F; Mariette X; Seror R
    Rheumatology (Oxford); 2020 Nov; 59(11):3275-3283. PubMed ID: 32259251
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Proactive infliximab is more effective than vedolizumab in inducing fecal calprotectin remission in inflammatory bowel disease.
    Fernandes SR; Rodrigues IC; Serrazina J; Botto IA; Bernardo S; Gonçalves AR; Valente A; Moura Santos P; Correia LA; Marinho RT
    Scand J Gastroenterol; 2022 Oct; 57(10):1202-1208. PubMed ID: 35599574
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Circulating exosomes express α4β7 integrin and compete with CD4+ T cells for the binding to Vedolizumab.
    Domenis R; Marino M; Cifù A; Scardino G; Curcio F; Fabris M
    PLoS One; 2020; 15(11):e0242342. PubMed ID: 33180848
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Benefit of measuring vedolizumab concentrations in inflammatory bowel disease patients in a real-world setting.
    Kolehmainen S; Ylisaukko-Oja T; Jokelainen J; Koivusalo M; Jokiranta TS; Sipponen T
    Scand J Gastroenterol; 2021 Aug; 56(8):906-913. PubMed ID: 34154506
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Translating Results from VARSITY to Real World: Adalimumab vs Vedolizumab as First-line Biological in Moderate to Severe IBD.
    Moens A; Verstockt B; Alsoud D; Sabino J; Ferrante M; Vermeire S
    Inflamm Bowel Dis; 2022 Aug; 28(8):1135-1142. PubMed ID: 34751766
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunological Variables Associated With Clinical and Endoscopic Response to Vedolizumab in Patients With Inflammatory Bowel Diseases.
    Coletta M; Paroni M; Alvisi MF; De Luca M; Rulli E; Mazza S; Facciotti F; Lattanzi G; Strati F; Abrignani S; Fantini MC; Vecchi M; Geginat J; Caprioli F
    J Crohns Colitis; 2020 Sep; 14(9):1190-1201. PubMed ID: 32100016
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early vedolizumab trough levels at induction in inflammatory bowel disease patients with treatment failure during maintenance.
    Liefferinckx C; Minsart C; Cremer A; Amininejad L; Tafciu V; Quertinmont E; Tops S; Devière J; Gils A; van Gossum A; Franchimont D
    Eur J Gastroenterol Hepatol; 2019 Apr; 31(4):478-485. PubMed ID: 30672828
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Impact of Vedolizumab on COVID-19 Outcomes Among Adult IBD Patients in the SECURE-IBD Registry.
    Agrawal M; Zhang X; Brenner EJ; Ungaro RC; Kappelman MD; Colombel JF
    J Crohns Colitis; 2021 Nov; 15(11):1877-1884. PubMed ID: 33884425
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prior Immunogenicity to Anti-TNF Biologics Is Not Associated with Increased Anti-drug Antibodies to Vedolizumab or Ustekinumab.
    Costable NJ; Borman ZA; Ji J; Dubinsky MC; Ungaro RC
    Dig Dis Sci; 2022 Jun; 67(6):2480-2484. PubMed ID: 34021427
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.